Literature DB >> 22112420

Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes.

Aaron M Gilson1, Scott M Fishman, Barth L Wilsey, Carlos Casamalhuapa, Hassan Baxi.   

Abstract

UNLABELLED: Prescription monitoring programs (PMPs) are designed to reduce medication diversion by identifying individuals obtaining the same medication from multiple providers (termed multiple provider episodes [MPEs]). This study determined whether recent changes to California's PMP influenced: 1) the extent that practitioners issue prescriptions for a variety of Schedule II opioids; and 2) the incidence of MPEs involving these opioids. Intervention time series of California's PMP data was used to determine the effect of requiring practitioners to transition from using triplicate prescription forms for Schedule II medications to security forms for all controlled substances. Outcome measures included changes in number of prescriptions issued for Schedule II long-acting or short-acting (SA) opioids and the MPEs involving these medications. Requiring a security form was associated with a sustained prescribing increase for SA hydromorphone, meperidine, and SA oxycodone; no prescribing changes were found for SA fentanyl, methadone, and SA morphine, or for any long-acting opioids. The same policy change, however, increased MPEs involving all opioids. Further effort is required to determine how California's PMP can continue to ensure availability of prescription opioids for medical use while better mitigating their diversion. PERSPECTIVE: Statistical model-building was used to evaluate the influence of changes to California's prescription monitoring program. The extent that practitioners prescribe Schedule II opioids and the incidence of people receiving prescriptions from multiple providers were measured. Such research illustrates the viability of evaluating drug control program impact on prescribing practice and potential diversion behaviors.
Copyright © 2012 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22112420      PMCID: PMC4063415          DOI: 10.1016/j.jpain.2011.09.006

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  21 in total

Review 1.  Maximizing the value of electronic prescription monitoring programs.

Authors:  David B Brushwood
Journal:  J Law Med Ethics       Date:  2003       Impact factor: 1.718

2.  Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations.

Authors:  M Weintraub; S Singh; L Byrne; K Maharaj; L Guttmacher
Journal:  JAMA       Date:  1991-11-06       Impact factor: 56.272

3.  Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities.

Authors:  S G Zullich; T H Grasela; J B Fiedler-Kelly; F M Gengo
Journal:  Ann Pharmacother       Date:  1992-04       Impact factor: 3.154

4.  Usefulness of prescription monitoring programs for surveillance--analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006.

Authors:  Nathaniel Katz; Lee Panas; Meelee Kim; Adele D Audet; Arnold Bilansky; John Eadie; Peter Kreiner; Florence C Paillard; Cindy Thomas; Grant Carrow
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-02       Impact factor: 2.890

Review 5.  Pain management and prescription monitoring.

Authors:  David E Joranson; Grant M Carrow; Karen M Ryan; Linda Schaefer; Aaron M Gilson; Patricia Good; John Eadie; Susan Peine; June L Dahl
Journal:  J Pain Symptom Manage       Date:  2002-03       Impact factor: 3.612

6.  Effect of a triplicate prescription law on prescribing of Schedule II drugs.

Authors:  K A Sigler; B G Guernsey; N B Ingrim; A S Buesing; J A Hokanson; E Galvan; W H Doutré
Journal:  Am J Hosp Pharm       Date:  1984-01

7.  Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine.

Authors:  Vincent Pradel; Elisabeth Frauger; Xavier Thirion; Eléonore Ronfle; Véronique Lapierre; Alain Masut; Christine Coudert; Olivier Blin; Joëlle Micallef
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-01       Impact factor: 2.890

Review 8.  The burden of the nonmedical use of prescription opioid analgesics.

Authors:  Aaron M Gilson; Paul G Kreis
Journal:  Pain Med       Date:  2009-07       Impact factor: 3.750

Review 9.  Opioid dependence and addiction during opioid treatment of chronic pain.

Authors:  Jane C Ballantyne; Steven K LaForge
Journal:  Pain       Date:  2007-05-04       Impact factor: 6.961

10.  Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy.

Authors:  Richard M Reisman; Pareen J Shenoy; Adam J Atherly; Christopher R Flowers
Journal:  Subst Abuse       Date:  2009-05-01
View more
  13 in total

1.  Increasing trends in Schedule II opioid use and doctor shopping during 1999-2007 in California.

Authors:  Huijun Han; Philip H Kass; Barth L Wilsey; Chin-Shang Li
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-08-19       Impact factor: 2.890

Review 2.  Harmonizing post-market surveillance of prescription drug misuse: a systematic review of observational studies using routinely collected data (2000-2013).

Authors:  Bianca Blanch; Nicholas A Buckley; Leigh Mellish; Andrew H Dawson; Paul S Haber; Sallie-Anne Pearson
Journal:  Drug Saf       Date:  2015-06       Impact factor: 5.606

3.  The use of a prescription drug monitoring program to develop algorithms to identify providers with unusual prescribing practices for controlled substances.

Authors:  Christopher Ringwalt; Sharon Schiro; Meghan Shanahan; Scott Proescholdbell; Harold Meder; Anna Austin; Nidhi Sachdeva
Journal:  J Prim Prev       Date:  2015-10

4.  Prescription drug monitoring and dispensing of prescription opioids.

Authors:  Joanne E Brady; Hannah Wunsch; Charles DiMaggio; Barbara H Lang; James Giglio; Guohua Li
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

5.  Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border.

Authors:  Tara Gomes; J Michael Paterson; Mariam Mukati; David Henry
Journal:  CMAJ Open       Date:  2015-04-02

Review 6.  Past-year prevalence of prescription opioid misuse among those 11 to 30years of age in the United States: A systematic review and meta-analysis.

Authors:  Ashly E Jordan; Natalie A Blackburn; Don C Des Jarlais; Holly Hagan
Journal:  J Subst Abuse Treat       Date:  2017-03-12

7.  Leading causes of unintentional and intentional injury mortality: United States, 2000-2009.

Authors:  Ian R H Rockett; Michael D Regier; Nestor D Kapusta; Jeffrey H Coben; Ted R Miller; Randy L Hanzlick; Knox H Todd; Richard W Sattin; Leslie W Kennedy; John Kleinig; Gordon S Smith
Journal:  Am J Public Health       Date:  2012-09-20       Impact factor: 9.308

Review 8.  The Association of State Opioid Misuse Prevention Policies With Patient- and Provider-Related Outcomes: A Scoping Review.

Authors:  Amanda I Mauri; Tarlise N Townsend; Rebecca L Haffajee
Journal:  Milbank Q       Date:  2019-12-04       Impact factor: 4.911

9.  Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis.

Authors:  Tara Gomes; David Juurlink; Zhan Yao; Ximena Camacho; J Michael Paterson; Samantha Singh; Irfan Dhalla; Beth Sproule; Muhammad Mamdani
Journal:  CMAJ Open       Date:  2014-10-01

10.  Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions.

Authors:  Richard A Deyo; Jessica M Irvine; Lisa M Millet; Todd Beran; Nicole O'Kane; Dagan A Wright; Dennis McCarty
Journal:  Health Aff (Millwood)       Date:  2013-02-13       Impact factor: 6.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.